Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vasopressin versus haemostatic tourniquet during open myomectomy
PACTR202505715829536Phase 3Not yet recruiting
- Sponsor
- Crystal Anejo
- Start
- May 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vasopressin in Fibromyoma (LM) (2 arms), sponsored by Crystal Anejo. Primary endpoint: Estimated intra-operative blood loss. Planned start May 2025; status: not yet recruiting.
02
Drugs
vasopressin
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on PACTR202505715829536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202505715829536.